Literature DB >> 18025095

Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia.

Damiana Chiavolini1, Joseph Alroy, Carol A King, Peter Jorth, Susan Weir, Guillermo Madico, John R Murphy, Lee M Wetzler.   

Abstract

Francisella tularensis can cause severe disseminated disease after respiratory infection. The identification of factors involved in mortality or recovery following induction of tularemia in the mouse will improve our understanding of the natural history of this disease and facilitate future evaluation of vaccine candidate preparations. BALB/c mice were infected intranasally with the live vaccine strain (LVS) of F. tularensis subsp. holarctica and euthanized at different stages of disease to analyze the induction of immune molecules, gross anatomical features of organs, bacterial burdens, and progression of the histopathological changes in lung and spleen. Tissue-specific interleukin-6 (IL-6), macrophage inflammatory protein 2, and monocyte chemotactic protein 1 were immune markers of mortality, while anti-LVS immunoglobulin M and IL-1beta were associated with survival. Moribund mice had enlarged spleens and lungs, while surviving mice had even more prominent splenomegaly and normal-appearing lungs. Histopathology of the spleens of severely ill mice was characterized by disrupted lymphoid follicles and fragmented nuclei, while the spleens of survivors appeared healthy but with increased numbers of megakaryocytes and erythrocytes. Histopathology of the lungs of severely ill mice indicated severe pneumonia. Lungs of survivors at early time points showed increased inflammation, while at late times they appeared healthy with peribronchial lymphoid aggregates. Our results suggest that host immune factors are able to affect bacterial dissemination after respiratory tularemia, provide new insights regarding the pathological characteristics of pulmonary tularemia leading to systemic disease, and potentially identify immune markers associated with recovery from the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025095      PMCID: PMC2223482          DOI: 10.1128/IAI.00862-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Typical and atypical presentations of extramedullary hemopoiesis.

Authors:  Christos S Georgiades; Edward G Neyman; Isaac R Francis; Michael B Sneider; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

2.  Sepsis: a follow-up of cytokine production in different phases of septic patients.

Authors:  Gloria Adriana Martins; Maria Da Gloria Da Costa Carvalho; Cerli Rocha Gattass
Journal:  Int J Mol Med       Date:  2003-05       Impact factor: 4.101

3.  Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis.

Authors:  M Fulop; P Mastroeni; M Green; R W Titball
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

4.  The pathology of untreated and antibiotic-treated experimental tularaemia in monkeys.

Authors:  A Baskerville; P Hambleton; A B Dowsett
Journal:  Br J Exp Pathol       Date:  1978-12

5.  Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea.

Authors:  X T Yan; T M Tumpey; S L Kunkel; J E Oakes; R N Lausch
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-09       Impact factor: 4.799

6.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

7.  Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis.

Authors:  Hua Shen; Wangxue Chen; J Wayne Conlan
Journal:  Microb Pathog       Date:  2004-08       Impact factor: 3.738

8.  Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.

Authors:  Hua Shen; Wangxue Chen; J Wayne Conlan
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

9.  Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.

Authors:  Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee; J Wayne Conlan
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica.

Authors:  Stephan Stenmark; Helena Lindgren; Arne Tärnvik; Anders Sjöstedt
Journal:  Microb Pathog       Date:  2003-08       Impact factor: 3.738

View more
  29 in total

1.  Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis.

Authors:  Luke C Kingry; Ryan M Troyer; Nicole L Marlenee; Helle Bielefeldt-Ohmann; Richard A Bowen; Alan R Schenkel; Steven W Dow; Richard A Slayden
Journal:  Microbes Infect       Date:  2010-11-09       Impact factor: 2.700

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

3.  Increased Resistance to Intradermal Francisella tularensis LVS Infection by Inactivation of the Sts Phosphatases.

Authors:  Kaustubh Parashar; Erik Kopping; David Frank; Vinaya Sampath; David G Thanassi; Nick Carpino
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

4.  Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways.

Authors:  Leah E Cole; Araceli Santiago; Eileen Barry; Tae Jin Kang; Kari Ann Shirey; Zachary J Roberts; Karen L Elkins; Alan S Cross; Stefanie N Vogel
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

6.  Host immune response and acute disease in a zebrafish model of Francisella pathogenesis.

Authors:  Lucia N Vojtech; George E Sanders; Carla Conway; Vaughn Ostland; John D Hansen
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

7.  Lethal pulmonary infection with Francisella novicida causes depletion of alphabeta T cells from lungs.

Authors:  Jyotika Sharma; Qun Li; Bibhuti B Mishra; Judy M Teale
Journal:  Cell Immunol       Date:  2009-04-07       Impact factor: 4.868

8.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

9.  Epitope-based vaccination against pneumonic tularemia.

Authors:  Stephen H Gregory; Stephanie Mott; Jennifer Phung; Jinhee Lee; Leonard Moise; Julie A McMurry; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

10.  Lethal pulmonary infection with Francisella novicida is associated with severe sepsis.

Authors:  Jyotika Sharma; Qun Li; Bibhuti B Mishra; Christopher Pena; Judy M Teale
Journal:  J Leukoc Biol       Date:  2009-04-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.